Estimation of efficiency and safety of new sucrosomial perooral form of iron in treatment of anemia in inflammatory bowel diseases
Abstract
The article describes the role of iron deficiency in the development of anemia in inflammatory bowel diseases (IBD), existing approaches to treatment. The problems of insufficient efficiency and poor tolerance of standard iron preparations are discussed, which is associated with the presence of malabsorbtion and chronic inflammation of the intestinal wall, the possibility of using a new oral form of sucrasomal iron is being studied. The aim of the study was to determine the efficacy and safety of the new Sucralomal oral form of iron Sideral Forte in patients with anemia in IBD. The materials of the study included data from 56 patients with anemia and IBD. In 28 patients, iron metabolism and anemia characteristics were studied in detail, and 28 others studied the efficacy and safety of antianemic treatment using Sideral Forte. The results of therapy showed a significant increase in the concentration of hemoglobin, serum iron for three months. Good tolerability of sucrasomal iron has been demonstrated.
About the Authors
N. I. Stuklov
Moscow Research Institute n.a. P.A. Herzen - a Branch of the National Medical Radiological Research Centre
Russian Federation
Russian Federation
O. V. Knyazev
Moscow Clinical Scientific and Practical Centre n.a. A.S. Loginov
Russian Federation
Russian Federation
A. I. Parfyonov
Moscow Clinical Scientific and Practical Centre n.a. A.S. Loginov
Russian Federation
Russian Federation
I. G. Basiladze
People’s Friendship University of Russia
Russian Federation
Russian Federation
A. V. Pivnik
People’s Friendship University of Russia; Moscow Clinical Scientific and Practical Centre n.a. A.S. Loginov
Russian Federation
Russian Federation
References
1. Wilson A., Reyes E., Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. Am J Med. 2004; 116 Suppl 7A: 44S-49S.
2. Morena F., Gisbert J.P. Anemia and inflammatory bowel disease. Rev Esp Enferm Dig. 2008; 100: 285-293.
3. Gasché C., Reinisch W., Lochs H., Parsaei B., Bakos S., Wyatt J., Fueger G.F., Gangl A. Anemia in Crohn's disease. Importance of inadequate erythropoietin production and iron deficiency. Dig Dis Sci. 1994; 39: 1930-1934.
4. Lakatos L., Pandur T., David G., Balogh Z., Kuronya P., Tollas A., Lakatos P.L. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World J Gastroenterol. 2003; 9: 2300-2307.
5. Revel-Vilk S., Tamary H., Broide E., Zoldan M., Dinari G., Zahavi I., Yaniv I., Shamir R. Serum transferrin receptor in children and adolescents with inflammatory bowel disease. Eur J Pediatr. 2000; 159: 585-589.
6. Vizia B., Poggi V., Conenna R., Fiorillo A., Scippa L. Iron absorption and iron deficiency in infants and children with gastrointestinal diseases. J Pediatr Gastroenterol Nutr. 1992; 14: 21-26.
7. Ormerod T.P. Observations on the incidence and cause of anaemia in ulcerative colitis. Gut. 1967; 8: 107-114.
8. Ormerod T.P. Anaemia in ulcerative colitis. Proc R Soc Med. 1968; 61: 931.
9. Стуклов Н.И. Железодефицитные синдромы при заболеваниях желудочно-кишечного тракта: перспективы лечения. Клиническая медицина, 94 (6): 410-418.
10. Gomollôn F., Gisbert J. Anemia and inflammatory bowel diseases. World J Gastroenterol. 2009 Oct 7; 15(37): 4659-4665.
11. Goodnough L.T., Nissenson A.R. Anemia and its clinical consequences in patients with chronic diseases.Am J Med. 2004; 116 Suppl 7A: 1S-2S.
12. Silva A.D., Mylonaki M., Rampton D.S. Oral iron therapy in inflammatory bowel disease: usage, tolerance, and efficacy. Inflamm Bowel Dis. 2003; 9: 316-320.
13. Лищинская А.А., Дроздов В.Н., Парфенов А.И., Князев О.В., Носкова К.К., Варванина Г.Г., Ткаченко Е.В. Клинико-патогенетические варианты анемии у больных воспалительными заболеваниями кишечника. В кн.: Тезисы 42-й научной сессии ЦНИИГ; 2016: 46-7.
14. Tsiolakidou G., Koutroubakis I.E. Stimulating erythropoiesis in inflammatory bowel disease associated anemia. World J Gastroenterol. 2007; 13: 4798-4806.
15. Weiss G., Goodnough L.T. Anemia of chronic disease. N Engl J Med. 2005; 352: 1011-1023.
16. Gasche C., Berstad A., Befrits R., Beglinger C., Dignass A., Erichsen K, Gomollon F., Hjortswang H., Koutroubakis I., Kulnigg S., et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis. 2007; 13: 1545-1553.
17. Стуклов Н.И., Семенова Е. Н. Железодефицитная анемия. Современная тактика диагностики и лечения. Современные критерии эффективности терапии // Клиническая медицина. - 2013. - № 12. - С. 61 -68.
18. Стуклов Н.И. Современная профилактика и лечение железодефицитной анемии в различных клинических группах в зависимости от тяжести анемии, возраста и пола // Поликлиника. 2014. - № 5 (1). - С. 49-56.
19. Rockey D.C. Treatment of iron deficiency. Gastroenterology. 2006; 130: 1367-1368.
20. Kawai M., Sumimoto S., Kasajima Y., Hamamoto T. A case of ulcerative colitis induced by oral ferrous sulfate. Acta Paediatr Jpn. 1992; 34: 476-478.
21. Reifen R., Matas Z., Zeidel L., Berkovitch Z., Bujanover Y. Iron supplementation may aggravate inflammatory status of colitis in a rat model. Dig Dis Sci. 2000; 45: 394-397.
22. Carrier J., Aghdassi E., Platt I., Cullen J., Allard JP. Effect of oral iron supplementation on oxidative stress and colonic inflammation in rats with induced colitis. Aliment Pharmacol Ther. 2001; 15: 1989-1999.
23. Aghdassi E., Carrier J., Cullen J., Tischler M., Allard JP. Effect of iron supplementation on oxidative stress and intestinal inflammation in rats with acute colitis. Dig Dis Sci. 2001; 46: 1088-1094.
24. Carrier J., Aghdassi E., Cullen J., Allard J.P. Iron supplementation increases disease activity and vitamin E ameliorates the effect in rats with dextran sulfate sodium-induced colitis. J Nutr. 2002; 132: 3146-3150.
25. Erichsen K., Hausken T., Ulvik R.J., Svardal A., Berstad A., Berge R.K. Ferrous fumarate deteriorated plasma antioxidant status in patients with Crohn disease. Scand J Gastroenterol. 2003; 38: 543-548.
26. Kulnigg S., Gasche C. Systematic review: managing anaemia in Crohn's disease. Aliment Pharmacol Ther. 2006; 24: 1507-1523.
27. Oldenburg B., Koningsberger J.C., van Berge Henegouwen G.P., Van Asbeck B.S., Marx J.J. Iron and inflammatory bowel disease. Aliment Pharmacol Ther. 2001; 15: 429-438.
28. Erichsen K., Ulvik R.J., Nysaeter G., Johansen J., Ostborg J., Berstad A., Berge R.K., Hausken T. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol. 2005; 40: 1058-1065.
29. Allen L.H. Iron supplements: scientific issues concerning efficacy and implications for research and programs. J Nutr. 2002; 132: 813S-819S.
30. Silverstein S.B., Rodgers G.M. Parenteral iron therapy options. Am J Hematol. 2004; 76: 74-78.
31. Tarantino G., Brilli E., Zambito Y., Giordano G., Equitani F. Sucrosomialiron: A new highly bioavaible oral iron supplement. Blood. 2015; 126 (23): 4561.
32. Indriolo, S. Signorelli, S. Greco, P. Ravelli. Comparison between liposo-mial iron and ferrous sulfate in patients with iron defi ciency anemia and inflammatory bowel disease. A pilot controlled study. Abstracts of the 20th National Congress of Digestive Diseases. Dig. Liv. Dis. 2014: 46.
33. Carrier J., Aghdassi E., Platt I., Cullen J., Allard J.P. Effect of oral iron supplementation on oxidative stress and colonic infl ammation in rats with induced colitis. Alimentary Pharmacol. Ther. 2001; 15 (12): 1989-99.
34. Tarantino G. New delivery system for high bioavailable iron supplements. Nutrafoods. 2013; 12: 71-8.
Review
For citations:
Stuklov N.I., Knyazev O.V., Parfyonov A.I., Basiladze I.G., Pivnik A.V. Estimation of efficiency and safety of new sucrosomial perooral form of iron in treatment of anemia in inflammatory bowel diseases. Medical alphabet. 2018;2(20):10-14. (In Russ.)
Views:
2420
Email this article 